Status: Not yet recruiting
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.
Participants needed: 1,360
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Jan 24, 2024
Eligibility criteria
Age: older than 18 years; [+4]
Previous or ongoing osteomyelitis or osteonecrosis of the jaw; dental or oral su... [+6]